Gilson Murata

Dr. Gilson Murata


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2016 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
MPM. E. P. Passos
M. E. P. Passos
HAHeloisa Helena De Oliveira Alves
Heloisa Helena De Oliveira Alves
Cesar Miguel Momesso SantosCesar Miguel Momesso Santos
Cesar Miguel Momesso Santos
FFFlavio Gomez Faria
Flavio Gomez Faria
GMGilson Murata
Gilson Murata
RGRenata Gorjao
Renata Gorjao
Palmitoleic acid (PA) is a n-7 monounsaturated fatty acid (MUFA) secreted by adipose tissue and related to decreased insulin resistance in peripheral tissues. Evidences have been shown that PA also decreased proinflammatory cytokine expression in cultured macrophages. Although studies have shown that other fatty acids (FAs) modulate several lymphocyte functions, the specific effect of PA on these cells is unknown. The aim of the present study was to evaluate the possible influence of PA on activation and differentiation of human lymphocytes in comparison to oleic acid (OA). Human lymphocytes were isolated from peripheral blood of health men and cultured in the presence of growing concentrations of PA or OA (5 to 200 μM), for 24 h. After that, cells were collected and cytotoxicity evaluated by flow cytometry. Then, we analyzed proliferative capacity in lymphocytes treated with non toxic concentrations of PA and OA (25 and 50 μM, respectively), in the presence or absence of concanavalin A (ConA). The Th1/Th2/Th17 cytokine production was determined by the Cytometric Bead Array. CD28 and CD95 surface expression and T regulatory cell percentage were determined by flow cytometry. We observed that PA is toxic to lymphocytes above 50 μM. PA promoted a decrease of lymphocyte proliferation stimulated by ConA in both concentrations. PA also decreased CD28 externalization and increased CD95. On the other hand, OA did not alter these parameters. In the same way, PA reduced IL6, IFN-gamma, TNF-alpha and IL17A production in both concentration and IL2 only at 50 μM (in the presence of ConA). OA promoted IFN-gamma reduction in both concentrations and an increase of IL-2, IL4 and IL10 at 25 μM. Both fatty acids decreased the percentage of T regulatory cells. In conclusion, PA promoted a suppressive effect on lymphocyte proliferation characterized by a decrease of Th1 and Th17 response, and co-stimulatory molecule (CD28). However, OA increased lymphocyte proliferation through IL2 production and Th2 response. These results also show a more suppressive effect of PA on lymphocytes in comparison to OA.

1 September 2020 in Cells
Verified
Journal Article
Open access
PDF file
FSFabio Takeo Sato
Fabio Takeo Sato
Yu-Anne YapYu-Anne Yap
Yu-Anne Yap
ACAmanda Crisma
Amanda Crisma
MPMariana Portovedo
Mariana Portovedo
GMGilson Murata
Gilson Murata
MVMarco Aurélio Vinolo
Marco Aurélio Vinolo
Obesity is linked with altered microbial short-chain fatty acids (SCFAs), which are a signature of gut dysbiosis and inflammation. In the present study, we investigated whether tributyrin, a prodrug of the SCFA butyrate, could improve metabolic and inflammatory profiles in diet-induced obese mice. Mice fed a high-fat diet for eight weeks were treated with tributyrin or placebo for another six weeks. We show that obese mice treated with tributyrin had lower body weight gain and an improved insulin responsiveness and glucose metabolism, partly via reduced hepatic triglycerides content. Additionally, tributyrin induced an anti-inflammatory state in the adipose tissue by reduction of Il-1β and Tnf-a and increased Il-10, Tregs cells and M2-macrophages. Moreover, improvement in glucose metabolism and reduction of fat inflammatory states associated with tributyrin treatment were dependent on GPR109A activation. Our results indicate that exogenous targeting of SCFA butyrate attenuates metabolic and inflammatory dysfunction, highlighting a potentially novel approach to tackle obesity.

Verified
Journal Article
Open access
PDF file
PSPaula Grippa Sant’ana
Paula Grippa Sant’ana
LTLoreta Casquel de Tomasi
Loreta Casquel de Tomasi
GMGilson Murata
Gilson Murata
DVDanielle Vileigas
Danielle Vileigas
GMGustavo Augusto Ferreira Mota
Gustavo Augusto Ferreira Mota
ACAntonio Cicogna
Antonio Cicogna
In pathological cardiac hypertrophy, the heart is more dependent on glucose than fatty acids. This shift in energy metabolism occurs due to several factors, including the oxygen deficit, which activates hypoxia-inducible factor-1α (HIF-1α), a critical molecule related to glucose metabolism. However, there are gaps regarding the behavior of key proteins in the glycolytic pathway and HIF-1α during the transition from hypertrophy to heart failure (HF). This study assesses the hypothesis that there is an early change and enhancement of HIF-1α and the glycolytic pathway, as well as an association between them during cardiac remodeling. Sham and aortic stenosis Wistar rats were analyzed at 2, 6, and 18 weeks and in HF (n = 10–18). Cardiac structure and function were investigated by echocardiogram. Myocardial glycolysis, the aerobic and anaerobic pathways and glycogen were analyzed by enzymatic assay, Western blot, and enzyme-linked immunosorbent assay (ELISA). The following were observed: increased left ventricular hypertrophy; early diastolic function change and severe systolic and diastolic dysfunction in HF; increased HIF-1α in the 2nd week and in HF; precocious alteration and intensification of glycolysis with a shift to anaerobic metabolism from the 6th week onwards; association between HIF-1α, glycolysis, and the anaerobic pathway. Our hypothesis was confirmed as there was an early change and intensification in glucose metabolism, alteration in HIF-1α, and an association between data during the progression from hypertrophy to heart failure.

13 February 2021 in Physiological Reports
Verified
Journal Article
Open access
PDF file
JPJoice Naiara Bertaglia Pereira
Joice Naiara Bertaglia Pereira
GMGilson Murata
Gilson Murata
FSFabio Takeo Sato
Fabio Takeo Sato
AMAline Rosa Marosti
Aline Rosa Marosti
CCCarla Carvalho
Carla Carvalho
RCRui Curi
Rui Curi
Goto–Kakizaki (GK) rat is an experimental model of spontaneous and non‐obese type‐2 diabetes mellitus—T2DM).GK rats exhibit decreased small intestinal area, increased crypt depth, villi height and th...

23 February 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
ASAline Santamarina
Aline Santamarina
Ruan C M MoraesRuan C M Moraes
Ruan C M Moraes
VNVictor Nehmi-Filho
Victor Nehmi-Filho
GMGilson Murata
Gilson Murata
JFJéssica Alves de Freitas
Jéssica Alves de Freitas
Ana Flávia Marçal PessoaAna Flávia Marçal Pessoa
Ana Flávia Marçal Pessoa
The use of natural products and derivatives for the prevention and control of non-communicable chronic diseases, such as type-2 diabetes (T2D), obesity, and hepatic steatosis is a way to achieve homeostasis through different metabolic pathways. Thus, male C57BL/6 mice were divided into the following groups: high-fat diet (HFD) vehicle, HFD + Supplemented, HFD + Supplemented_S, and isolated compounds. The vehicle and experimental formulations were administered orally by gavage once a day over the four weeks of the diet (28 consecutive days). We evaluated the energy homeostasis, cytokines, and mitochondrial gene expression in these groups of mice. After four weeks of supplementation, only the new nutraceutical group (HFD + Supplemented) experienced reduced fasting glycemia, insulin, HOMA index, HOMA-β, dyslipidemia, ectopic fat deposition, and hepatic fibrosis levels. Additionally, the PPARγ coactivator 1 α (Pgc-1α), interleukin-6 (Il-6), and interleukin-10 (Il-10) gene expression were augmented, while hepatic steatosis decreased and liver parenchyma was recovered. The glutathione-S-transferase activity status was found to be modulated by the supplement. We discovered that the new nutraceutical was able to improve insulin resistance and hepatic steatosis mainly by regulating IL-6, IL-10, and Pgc-1α gene expression.

12 September 2019 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
Cesar Miguel Momesso SantosCesar Miguel Momesso Santos
Cesar Miguel Momesso Santos
VDVinicius Diniz
Vinicius Diniz
Andre BachiAndre Bachi
Andre Bachi
LOLaiane Cristina dos Santos de Oliveira
Laiane Cristina dos Santos de Oliveira
TGTamara Ghazal
Tamara Ghazal
RGRenata Gorjao
Renata Gorjao
Background: Obesity can lead to a chronic systemic inflammatory state that increases the risk of cancer development. Therefore, this study aimed to evaluate the alterations in tumor non-infiltrated lymphocytes function and melanoma growth in animals maintained on a high-fat diet and/or moderate physical exercise program in a murine model of melanoma.Methods: Female mice were randomly divided into eight groups: 1) normolipidic control (N), 2) normolipidic + melanoma (NM), 3) high-fat control (H), 4) high-fat + melanoma (HM), 5) normolipidic control + physical exercise (NE), 6) normolipidic melanoma + physical exercise (NEM), 7) high-fat control + physical exercise (HE), and 8) high-fat melanoma + physical exercise (HEM). After 8 weeks of diet treatment and/or moderate physical exercise protocol, melanoma was initiated by explanting B16F10 cells into one-half of the animals.Results: Animals fed a high-fat diet presented high-energy consumption (30%) and body weight gain (H and HE vs N and NE, 37%; HM and HEM vs NM and NEM, 73%, respectively), whether or not they carried melanoma explants. Although the tumor growth rate was higher in animals from the HM group than in animals from any other sedentary group, it was reduced by the addition of a physical exercise regimen. We also observed an increase in stimulated peripheral lymphocyte proliferation and a decrease in the T-helper 1 response in the HEM group.Conclusions: The results of the present study support the hypothesis that altering function of tumor non-infiltrated lymphocytes via exercise-related mechanisms can slow melanoma progression, indicating that the incorporation of a regular practice of moderate-intensity exercises can be a potential strategy for current therapeutic regimens in treating advanced melanoma.